Spartan Fund Management Inc. acquired a new stake in Biotech Acquisition (NASDAQ:BIOT – Get Rating) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 24,530 shares of the company’s stock, valued at approximately $302,000.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Walleye Capital LLC purchased a new position in Biotech Acquisition in the fourth quarter valued at $930,000. OMERS ADMINISTRATION Corp increased its holdings in Biotech Acquisition by 336.2% in the first quarter. OMERS ADMINISTRATION Corp now owns 247,005 shares of the company’s stock valued at $2,433,000 after buying an additional 190,377 shares in the last quarter. Glazer Capital LLC purchased a new position in Biotech Acquisition in the fourth quarter valued at $1,088,000. Aristeia Capital LLC purchased a new position in Biotech Acquisition in the 4th quarter valued at about $11,306,000. Finally, D. E. Shaw & Co. Inc. lifted its position in shares of Biotech Acquisition by 75.4% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 929,085 shares of the company’s stock valued at $9,142,000 after acquiring an additional 399,255 shares in the last quarter. Hedge funds and other institutional investors own 86.02% of the company’s stock.
Biotech Acquisition Stock Performance
NASDAQ BIOT opened at $9.91 on Friday. The stock’s 50 day simple moving average is $9.87 and its 200-day simple moving average is $9.83. Biotech Acquisition has a 1-year low of $8.30 and a 1-year high of $10.41.
Biotech Acquisition Profile
Biotech Acquisition Company does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.
- Get a free copy of the StockNews.com research report on Biotech Acquisition (BIOT)
- No One Told These 3 Stocks It’s a Down Week
- Is There a Cure for What is Ailing Teladoc Stock?
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
Receive News & Ratings for Biotech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biotech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.